Dsm IP Assets B.v.

University College Cork

The Procter Gamble Company

Compagnie Gervais Danone

Precisionbiotics Group Limited

Alimentary Health Limited

Università Degli Studi Di Bari Aldo Moro

Douwe Van Sinderen

Roelof Hendrik Matthijs Kouwen

Brian McDonnell

Jennifer Mahony

Raymond A Grant

Wenzhu Steven Zhao

Jun Xu

Liam Diarmuid O'Mahony

Duane Larry Charbonneau

Charles Carson Bascom

Pim Van Hee

Raymond Alan Grant

Peggy Garault

Tamara Smokvina

Wenzhu Zhao

Gerald Christopher O'Sullivan

Raffaella Di Cagno

Marco Gobbetti

Maria De Angelis

Yuli Song

Stuart Ainsworth

Witold Kot

Pieter Emiel Verloren Van Themaat

Finn Vogensen

Michelle Cronin

Mark Tangney

Song Yuli

Wenzhu (Steven) Zhao

Debbie Watson

Mary O'Connell Motherway

Laurens Leendert Hanemaaijer

Van Pim Hee

Alessia Lanera

Erica Pontonio

Pieter Emiel Ver Loren Van Themaat

Roelof Hendrik Kouwen

Liam O'mahony

Duane Larry Charbonneu

Liam O'mahoney

Brian Mcdonnell

The present invention relates to a starter culture comprising at least twostrains, wherein a first and a secondstrain are chosen from RGP group 1, RGP group 2, RGP group 3 and RGP group 4, with the proviso that the first and secondstrains do not belong to the same RGP group.

starter cultures

The multiple embodiments described herein comprise the genome of a probioticbifidobacteria strain and genes encoded by the genome. Various novelare described.

A kit useful for determining the phage susceptibility of one or more strains ofis described. The disclosure also describes methods for formulation of mixed defined starter cultures using strains from different phage sensitivity groups.

Methods and kits to determine the sensitivity of strains ofbacteria to phage infection

The present invention relates to a kit suitable for detection ofinfecting phages, said kit comprising: (a) a first primer pair suitable to generate an amplicon characteristic for a 987 phage; and (b) a second primer pair suitable to generate an amplicon characteristic for a 5093 phage. Further, the present invention relates to a method for detecting the presence ofinfecting phages in a sample.

Bacteriophage detection

Bacteriophage Insensitive Mutants (BIMs) of threeparent strains were generated and characterized for phage sensitivity, sedimentation rate, cell chain length, phage adsorption and CRISPR loci alterations. Several BIMs showed an altered sedimentation phenotype as well as an increase cell chain length, reduced phage sensitivity, reduced phage adsorption and 100% identity in three CRISPR loci. The results show that the derived BIMs have become phage-resistant through a mechanism other than CRISPR.

Phage insensitive

The present invention provides a method for the construction of a bacteriophage-insensitive mutant of aparent strain whereby the bacteriophage insensitivity is not based on the CRISPR resistance mechanism but based on another mechanism. The method provides a protocol by which this can be achieved by inactivating one or more of the CRISPR systems present in a given strain. The invention also provides the bacteriophage-insensitive mutants as well as their use in a process for making a dairy product.

[object Object]

The present invention concerns a method for genetically transforming astrain comprising a step of methylation of a shuttle vector in anor a Gram-positive bacterium strain by two type II DNA methyltransferases from a: a methyltransferase enzyme that methylates the adenine base at position 4 of the nucleotide sequence RTCAGG and a methyltransferase enzyme that methylates the cytosine base at position 4 of the nucleotide sequence GGWCC. The present invention also concerns genetic tools and culture media useful for carrying out said method.

Genetic transformation of bifidobacteria

Bifidobacterium longum

The current invention relates to the use of a bacterial species in the preparation of a composition adapted for oral administration for the delivery of an agent to a site in the body. The site in the body may be an organ or a tumour site. The bacterial species is a food grade, non-pathogenic, gram-positive bacteria capable of anaerobic growth.

Orally administered bacteria as vehicles for systemic delivery of agents

Growing community of inventors

Carrigrohane, Ireland

Douwe Van Sinderen